Oppenheimer Increases Tyra Biosciences (NASDAQ:TYRA) Price Target to $33.00

Tyra Biosciences (NASDAQ:TYRA) had its price target hoisted by research analysts at Oppenheimer from $25.00 to $33.00 in a research note issued to investors on Thursday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Oppenheimer’s target price would suggest a potential upside of 35.47% from the stock’s current price.

Several other equities analysts have also recently weighed in on TYRA. Piper Sandler began coverage on Tyra Biosciences in a report on Thursday, August 15th. They issued an “overweight” rating and a $33.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $23.00 price objective on shares of Tyra Biosciences in a report on Wednesday, July 3rd. Finally, Wedbush restated an “outperform” rating and issued a $28.00 price objective on shares of Tyra Biosciences in a report on Thursday, August 8th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Tyra Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $26.40.

Tyra Biosciences Trading Up 1.5 %

TYRA stock opened at $24.36 on Thursday. The stock has a 50-day moving average price of $21.29 and a two-hundred day moving average price of $18.73. The stock has a market cap of $1.28 billion, a PE ratio of -14.50 and a beta of 1.01. Tyra Biosciences has a 1 year low of $10.38 and a 1 year high of $25.14.

Tyra Biosciences (NASDAQ:TYRA) last released its earnings results on Wednesday, August 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.09. On average, analysts forecast that Tyra Biosciences will post -1.53 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Todd Harris sold 5,698 shares of Tyra Biosciences stock in a transaction dated Thursday, September 19th. The stock was sold at an average price of $24.31, for a total transaction of $138,518.38. Following the completion of the transaction, the chief executive officer now owns 1,496,729 shares in the company, valued at $36,385,481.99. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 15.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Tyra Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of TYRA. HighVista Strategies LLC bought a new position in Tyra Biosciences during the second quarter worth about $257,000. Rhumbline Advisers lifted its position in Tyra Biosciences by 12.3% during the second quarter. Rhumbline Advisers now owns 23,572 shares of the company’s stock worth $377,000 after acquiring an additional 2,574 shares during the last quarter. Victory Capital Management Inc. lifted its position in Tyra Biosciences by 53.4% during the fourth quarter. Victory Capital Management Inc. now owns 50,220 shares of the company’s stock worth $696,000 after acquiring an additional 17,490 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Tyra Biosciences by 32.8% during the second quarter. Bank of New York Mellon Corp now owns 58,087 shares of the company’s stock worth $929,000 after acquiring an additional 14,352 shares during the last quarter. Finally, Oppenheimer & Co. Inc. acquired a new stake in Tyra Biosciences during the first quarter worth approximately $977,000. Institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.